Ongoing non-dilutive funding strategy for biotech companies

Advisory engagements give biotech leadership a scientific sounding board as evidence, opportunities, and priorities change. The work centers on decisions across the funding process.

• Funding landscape assessment and opportunity prioritization
• SBIR versus STTR decisions and institute/program fit
• Sequencing opportunities around scientific and development milestones
• Application readiness and independent assessment of emerging risks
• Reviewer feedback and decisions about resubmission or redirection
• Portfolio-level funding strategy and allocation of limited team resources

An agreed cadence of advisory discussions, focused review of relevant materials, and documented decisions and next steps. Scope and deliverables are tailored to the company’s priorities before the engagement begins.

Bring your development roadmap, current funding options, evidence base, and the decisions ahead. We define the questions to resolve, agree a working cadence, and revisit priorities as new information arrives.

Advisory supports scientific judgment and funding decisions. Full grant production, application drafting, and submission administration are outside the core service.